DGAP-News: STADA founds a subsidiary in Australia - business activities expected to commence in the third quarter of 2012
(firmenpresse) - DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA founds a subsidiary in Australia - business activities expected
to commence in the third quarter of 2012
27.03.2012 / 07:25
---------------------------------------------------------------------
Bad Vilbel, March 27, 2012 - In the current first quarter of 2012 STADA
Arzneimittel AG founded a subsidiary based in Sydney, Australia, under the
name STADA Pharmaceuticals Australia Pty Ltd, which is expected to commence
its business activities in the third quarter of 2012.
Two managers with decades of experience in the pharmaceutical industry will
advance the establishment of the Australian STADA subsidiary.
The sales of the Australian generics market currently amounts to approx.
AUD 1 billion (approx. EUR 820 million) with average annual growth of
approx. 5%. In view of expiring patents from the year 2012 to 2014 with
sales at current ex-factory prices in the amount of approx. AUD 2.1 billion
(approx. EUR 1.72 billion), high growth is expected in the Australian
generics market. Further growth opportunities are also emerging as a result
of the current relatively low generics penetration of less than 40% in
Australia.
In order to be able to benefit from this growth potential, the new STADA
sales company will initially market a number of in-licensed off-patent
products, which will be supplemented successively by additional products
also from STADA's own pipeline.
The STADA Group's initial investment for the activities in the Australian
market amount to approx. AUD 2 million (approx. EUR 1.64 million).
By founding the new subsidiary, STADA would like to benefit from the growth
opportunities available in the Australian generics market as well as
further expand its presence in the growth region Asia/Pacific.
Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications(at)stada.de /
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
27.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications(at)stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAXListed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
162283 27.03.2012
Themen in dieser Pressemitteilung:
stada-founds-a-subsidiary-in-australia
business-activities-expected-to-commence-in-the-third-quarter-of-2012
Unternehmensinformation / Kurzprofil:
Datum: 27.03.2012 - 07:25 Uhr
Sprache: Deutsch
News-ID 128605
Anzahl Zeichen: 9497
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STADA founds a subsidiary in Australia - business activities expected to commence in the third quarter of 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
STADA Arzneimittel AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
